Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
80.21
+0.95 (1.20%)
At close: Dec 29, 2025, 4:00 PM EST
80.82
+0.61 (0.76%)
After-hours: Dec 29, 2025, 7:50 PM EST
Mirum Pharmaceuticals Employees
Mirum Pharmaceuticals had 322 employees as of December 31, 2024. The number of employees increased by 58 or 21.97% compared to the previous year.
Employees
322
Change (1Y)
58
Growth (1Y)
21.97%
Revenue / Employee
$1,465,199
Profits / Employee
-$128,643
Market Cap
4.12B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 322 | 58 | 21.97% |
| Dec 31, 2023 | 264 | 68 | 34.69% |
| Dec 31, 2022 | 196 | 59 | 43.07% |
| Dec 31, 2021 | 137 | 69 | 101.47% |
| Dec 31, 2020 | 68 | 35 | 106.06% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MIRM News
- 7 days ago - Mirum: Maintaining Buy Rating On VOLIXIBAT PSC Treatment Data Q2 2026 - Seeking Alpha
- 10 days ago - Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX - Business Wire
- 19 days ago - Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 21 days ago - Mirum Pharmaceuticals, Inc. (MIRM) M&A Call Transcript - Seeking Alpha
- 21 days ago - Mirum Pharma to buy Bluejay Therapeutics for up to $820 million - Reuters
- 21 days ago - Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease - Business Wire
- 27 days ago - Mirum Pharmaceuticals, Inc. (MIRM) Presents at Evercore 8th Annual Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome - Business Wire